Blog
RSS FeedPosted by Michael Wonder on 29 Oct 2020
NICE announces start of review of nusinersen Managed Access Agreement
29 October 2020 - NICE has today announced that it has begun the process to review data collected as part of ...
Posted by Michael Wonder on 03 Jun 2018
Tesaro's ovarian cancer drug Zejula added to Cancer Drugs Fund
1 June 2018 - Tesaro's ovarian cancer drug Zejula (niraparib), the first PARP inhibitor shown to be effective in patients ...
Posted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung ...
Posted by Michael Wonder on 07 Dec 2017
Roche’s Tecentriq available via CDF
7 December 2017 - Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for ...
Posted by Michael Wonder on 16 Oct 2017
Roche’s skin cancer drug Erivedge pulled from CDF
13 October 2017 - Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute ...
Posted by Michael Wonder on 05 Jul 2017
Merck’s Keytruda, Lilly’s Lartruvo available via CDF
5 July 2017 - Patients with certain forms of lung cancer or sarcoma have now gained access to two new ...
Posted by Michael Wonder on 24 Aug 2016
NICE approves new cancer drugs for routine NHS use
24 August 2016 - Two cancer treatments, previously only available to patients through the Cancer Drugs Fund, will now be routinely ...